Across TCGA pan-cancer cohorts, PATE3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PATE3 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher PATE3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PATE3 expression acts as an unfavorable survival marker.
READ and COAD are the cancer types where PATE3 Mutation most reproducibly stratifies survival.